Skip to content
  • Our Focus
    • Pterygium Overview
    • Pterygium Therapy
    • Pinguecula Overview
    • Pinguecula Therapy
  • Technology
    • Multi-Kinase Inhibitors (MKIs)
    • Semi-Fluorinated Alkanes+ (SFA+)
  • Pipeline
    • CBT-001
    • CBT-004
    • CBT-009
    • CBT-199
    • Active Clinical Trials
  • About
    • Overview
    • Management
    • Scientific Advisory Board
    • Our Partners
  • News
  • InvestorRelations
    • Corporate Presentation Deck
    • How to Buy Cloudbreak Pharma Stock
    • Announcements & Presentations
    • Financial Reports
    • Listing Documents
    • Corporate Governance
    • Arrangement of Electronic Dissemination of Corporate Communications
    • Stock Chart
  • Contact
  • English
    • 繁體中文
    • 简体中文
  • Our Focus
    • Pterygium Overview
    • Pterygium Therapy
    • Pinguecula Overview
    • Pinguecula Therapy
  • Technology
    • Multi-Kinase Inhibitors (MKIs)
    • Semi-Fluorinated Alkanes+ (SFA+)
  • Pipeline
    • CBT-001
    • CBT-004
    • CBT-009
    • CBT-199
    • Active Clinical Trials
  • About
    • Overview
    • Management
    • Scientific Advisory Board
    • Our Partners
  • News
  • InvestorRelations
    • Corporate Presentation Deck
    • How to Buy Cloudbreak Pharma Stock
    • Announcements & Presentations
    • Financial Reports
    • Listing Documents
    • Corporate Governance
    • Arrangement of Electronic Dissemination of Corporate Communications
    • Stock Chart
  • Contact
  • English
    • 繁體中文
    • 简体中文

Our Focus

  • Pterygium
  • Pinguecula
  • Multi-Kinase Inhibitors
  • SFA+ Platform

united states

info@cloudbreakpharma.com

8921 Research Dr.
Irvine, CA 92618

View Map

HONG KONG

Suite 23A11
23A/F, Tower 2, The Gateway
Harbour City
Kowloon, Hong Kong

View Map

© 2026 Cloudbreak Pharma All Rights Reserved.

Cloudbreak Pharma FCOI

Privacy Policy

Terms of Service